Impact Therapeutics Inc. has divulged heteroaryl compounds acting as ATP-dependent RNA helicase A (DHX9) inhibitors intended for use in the treatment of cancer.
Hubei Polytechnic University (Huangshi, China) scientists and collaborators aimed to develop potential tubulin polymerization inhibitors that may also synergize with immunotherapies for cancer treatment.
Nextpoint Therapeutics Inc. has obtained IND clearance from the FDA to initiate clinical development of NPX-372, a first-in-class B7-H7-targeted T-cell engager (TCE) for the treatment of patients with solid tumors.
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, representing approximately 75-85% of all cases. Often considered preventable, primary liver cancer ranks as the sixth most frequently diagnosed cancer and the third leading cause of cancer deaths worldwide. Through a multi-institutional effort, researchers have identified activated ATF6α as a driver of HCC that suppresses immune defenses, predicts response to immune checkpoint therapy, and represents a potential target for intervention.
Scientists from the Korea Research Institute of Chemical Technology and Yonsei University have identified N4-(indolin-7-yl)-N2-(2-alkoxypyridin-3-yl)pyrimidine-2,4-diamine derivatives acting as EGFR (HER1; erbB1) and/or HER2 (erbB2) mutant inhibitors and therefore reported to be useful for the treatment of cancer.
Newco ALTx Therapeutics Ltd. has launched with a £12.55 million (US$17.1 million) seed round to develop inhibitors of the alternative lengthening of telomeres (ALT) pathway, by which 10% to 15% of cancers become immortal.
Tyk Medicines Inc. has identified N-acetyl-β-D-glucosaminidase (O-GlcNAcase; OGA) inhibitors described as potentially useful for the treatment of cancer, metabolic diseases, Alzheimer’s disease and progressive supranuclear palsy.
Researchers from the Institut National De La Sante Et De La Recherche Medicale, Universite de Bordeaux and Universite de Paris Cite have reported indane 1,3-dione derivatives acting as furin (PACE; PCSK3) inhibitors potentially useful for the treatment of cancer.
RSS
